MapLight Therapeutics, Inc. (MPLT) vs Prothena Corporation plc (PRTA)
A side-by-side comparison of MapLight Therapeutics, Inc. and Prothena Corporation plc across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
MPLT
MapLight Therapeutics, Inc.
$9.90HealthcareDelayed quote: Oct 6, 2026, 2:25 PM EDT
PRTA
Prothena Corporation plc
$8.03HealthcareDelayed quote: Oct 6, 2026, 2:25 PM EDT
Total return — MPLT vs PRTA
growth of $100 · dividends reinvested · last 1yMPLT -49.4% (-49.4%/yr)PRTA -15.2% (-15.2%/yr)PRTA compounded faster over this window
MPLT PRTA
MPLT vs PRTA: by the numbers
- •PRTA is the larger company ($420M vs $420M market cap).
- •Both run net losses; MPLT's is the smaller (0.00% vs -80.67% net margin).
Metrics side by side
Valuation
| Metric | MPLT | PRTA |
|---|---|---|
| Forward P/E | N/A | 72.99 |
| P/S ratio | N/A | 7.71 |
| P/B ratio | 1.21 | 1.47 |
Profitability
| Metric | MPLT | PRTA |
|---|---|---|
| Gross margin | 0.00% | 61.77% |
| Operating margin | 0.00% | -1905.82% |
| Net margin | 0.00% | -80.67% |
| ROE | -65.99% | -15.33% |
| ROIC | -69.35% | -21.36% |
Growth (annualized)
| Metric | MPLT | PRTA |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 62.57% |
| Total return CAGR (5Y) | N/A | -35.08% |
Go deeper
Dig into the metrics
MapLight Therapeutics ROEProthena ROEMapLight Therapeutics operating marginProthena operating marginMapLight Therapeutics revenue growthProthena revenue growthMapLight Therapeutics free cash flowProthena free cash flow
MapLight Therapeutics & Prothena appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.